Successes and limitations of targeted cancer therapy in colon cancer.

摘要: Constant development of chemotherapy and more recently the introduction VEGF- epidermal growth factor receptor (EGFR)-directed agents have improved significantly treatment patients with colorectal cancer. In adjuvant setting, especially for UICC stage III colon cancer patients, fluoropyrimidine in combination oxaliplatin is usually standard care. With some surprise, both VEGF inhibitors (for all patients) EGFR KRAS exon 2 mutant tumors) failed to improve chemotherapy. Also, adding an antibody FOLFOX as perioperative resectable wild-type liver metastases was not successful. However, metastatic disease harboring a RAS tumor are no doubt candidates plus antibody. liver-limited disease, may become following intensive (including disease), which result cure or prolonged survival. case tumors, median survival unresectable approaches now 3 years if antibodies used first line. There little evidence first-line considered. inhibitors, however, very potent drugs be combined second-line treatment.